Skip to main content
Clinical Trials/NCT05509283
NCT05509283
Completed
Not Applicable

Nudging Flu Vaccination in Patients at Moderately High Risk for Flu and Flu-related Complications

Geisinger Clinic1 site in 1 country40,671 target enrollmentSeptember 13, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Influenza
Sponsor
Geisinger Clinic
Enrollment
40671
Locations
1
Primary Endpoint
Flu vaccination
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This study will test the relative efficacy of high-risk messages in increasing flu shot rates in patients at moderately high risk for flu and complications (those in the top 11-20% of risk). It will also examine whether informing patients that their high-risk status was determined by analyzing their medical records or by an artificial intelligence (AI) / machine-learning (ML) algorithm analyzing their medical records will affect the likelihood of receiving a flu vaccine.

Detailed Description

Almost everyone age 6 months or older can benefit from the vaccine, which can reduce illnesses, missed work, hospitalizations, and death by reducing the likelihood of contracting influenza. Flu shots are particularly important for patients at high risk of experiencing severe outcomes. In the 2020-21 and 2021-22 flu seasons, the study team sent messages to Geisinger patients in the top 10% of risk for flu and complications according to an artificial intelligence algorithm. Messages that disclosed patients' risk status significantly increased flu vaccination rates. Additionally, messages that included risk information were most effective in patients at relatively lower risk (those in the top 4-10%) compared with those at the highest risk (top 3%). The present work will test the effectiveness of high-risk messages in patients who are in the top 11-20% of risk, at high risk but lower than previous studies. These communications will inform patients they are at high risk with either (a) no additional explanation, (b) an explanation that this determination comes from an analysis of their medical records, or (c) the additional explanation that an AI or ML algorithm made this determination.

Registry
clinicaltrials.gov
Start Date
September 13, 2022
End Date
October 26, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Christopher F Chabris, PhD

Professor

Geisinger Clinic

Eligibility Criteria

Inclusion Criteria

  • Included on a list of active Geisinger patients (all patients on this list attended at least one primary care appointment at Geisinger between 10/1/2008 and 4/13/2022, and either had a Geisinger primary care provider assigned as of April 2022, or were in the Electronic Health Record \[EHR\] since at least September 2021 and had at least one encounter in 2020-2022)
  • Aged 18 or older
  • In the top 11-20% of risk for flu and flu complications, according to Medial's flu complications machine learning algorithm (which operates on coded EHR data)
  • Has a Geisinger PCP assigned as of August 2022
  • Has had an encounter in the last 2 years as of August 2022
  • Exclusion criteria:
  • Cannot be contacted via any of the communication modalities (e.g., letter, patient portal, SMS) being used in the study, either due to insufficient/missing contact information in the EHR or because they opted out of all modalities

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Flu vaccination

Time Frame: Within 6 weeks of the patient's study start date

Received a flu vaccination within within 6 weeks of the patient's study start date

Study Sites (1)

Loading locations...

Similar Trials